Due to recent advances in cancer therapy, immune checkpoint inhibitors (ICIs) are new classes of drugs targeting programmed cell death protein 1-ligand 1 (PD-L1, synonym CD274, B7) homolog 1) or its receptor (PD-1, synonym CD 279) (1). This evidence concerns the gene PDCD1 and cancer.